Sam Vara wrote: ↑Mon Jun 07, 2021 2:46 pm
Dan74 wrote: ↑Mon Jun 07, 2021 1:44 pm
The current estimate of TTS is 1 in 50 000 in AZ and rising but fortunately they are getting better at treating it. Still Europe's fatality rate is at 18% it appears
I hope it didn't come across wrong - 18% from the 1 in 50 000 TTS cases, not 18% from all vaccinated with AZ. That would've been a horrific catastrophe.
As it is, I don't know if it's really worth it for young people to subject themselves to this risk, since their COVID risk isn't high at all:
https://www.thelancet.com/journals/lanc ... 3/fulltext
In this article, if I understand it correctly, it says that 22 people between 10-19 years of age died of COVID in the UK within a year, that's out of over 7.5 million. If 1 in 300 000 die of TTS from the AZ vaccine, and all of the 7.5 million are vaccinated, that's about 25. Since catching COVID is less likely now, whereas the vaccine is given, I would not let children and adolescents have AZ. It is not to their benefit. Except for someone in the high COVID risk group.
Plus, AZ is not especially effective.
In Australia, it's been stopped for the under-50's. There's been a lot more TTS cases among the under-50. Here, in Switzerland, it is not approved at all, in spite of them filing for approval. The regulator says that they are missing clinical data from AZ, in order to make a decision. A natural question is whether other regulators had that data (and the Swiss one somehow didn't get it) or have they made their decision without it.